The U.S. Health Resources and Services Administration (HRSA) told 340B Report yesterday in response to an inquiry that 340B program administrative dispute resolution (ADR) panels have been assigned—signaling that an unknown number of proceedings might begin on ADR petitions by covered entities against drug manufacturers for denying 340B discounts on drug dispensed by contract pharmacies.
“HRSA can confirm that panels have been assigned. We have no other comment at this time,” an agency spokesperson said late yesterday afternoon.
The U.S. Health Resources and Services Administration (HRSA) told 340B Report yesterday in response to an inquiry that 340B program administrative dispute resolution (ADR) panels have been assigned—signaling that an unknown number of proceedings might begin on ADR petitions by covered entities against drug manufacturers for denying 340B discounts on drug dispensed by contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
